Drug Type Small molecule drug |
Synonyms DEP® SN38, DEP® irinotecan, SN38 dendrimer nanoparticle |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H20N2O5 |
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N |
CAS Registry86639-52-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 07 Aug 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United Kingdom | 07 Aug 2019 | |
Colorectal Cancer | Phase 2 | Australia | 07 Aug 2019 | |
Colorectal Cancer | Phase 2 | United Kingdom | 07 Aug 2019 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | Australia | 07 Aug 2019 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | United Kingdom | 07 Aug 2019 | |
Ovarian Cancer | Phase 2 | Australia | - |